Eisai Asks Appeals Court To Order DEA To Make Rule, Allow New Epilepsy Drug's Sale

WASHINGTON, D.C. - Japanese drug maker Eisai Inc. on Aug. 19 petitioned the District of Columbia federal appeals court for a writ of mandamus to force the U.S. Drug Enforcement Agency (DEA) to issue a rule that will allow the company to move forward with the marketing of its approved new epilepsy drug (In re Eisai Incorporated, No. 13-1243, D.C. Cir.).

Access this news story on lexis.com®